Waypoint Capital completed the acquisition of a 70% stake in Allergy Partners.

Waypoint Capital, an entrepreneurial private investment firm, completed the acquisition of a 70% stake in Allergy Partners, the largest US group of single-specialty allergy and asthma practices. Financial terms were not disclosed. "We are excited to be partnering with Waypoint Capital as Allergy Partners looks to increase access to our services for even more patients across the country. Our mission is to be leaders in the development and delivery of high-quality health care for patients with asthma and allergic disease. Our partnership with Waypoint will further that mission as we continue to execute on our strategic initiatives, further build our vast care network, and promote continued research and innovation in the field of allergy and asthma care," David Brown, Allergy Partners CEO.